A61K 35/13
Tumour cells, irrespective of tissue of origin
Official title: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
A61K35/13 (Tumour cells, irrespective of tissue of origin) appears on 317 US grants and 511 published applications in this corpus.
Search patents in A61K- Granted patents
- 317
- Published applications
- 511
- Assignees
- 317
- Inventors
- 945
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 3 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 5 | 0 |
| 1999 | 5 | 0 |
| 2000 | 7 | 0 |
| 2001 | 8 | 6 |
| 2002 | 2 | 9 |
| 2003 | 7 | 10 |
| 2004 | 5 | 9 |
| 2005 | 6 | 16 |
| 2006 | 7 | 18 |
| 2007 | 4 | 16 |
| 2008 | 3 | 20 |
| 2009 | 12 | 18 |
| 2010 | 11 | 27 |
| 2011 | 8 | 31 |
| 2012 | 11 | 17 |
| 2013 | 11 | 12 |
| 2014 | 17 | 21 |
| 2015 | 18 | 19 |
| 2016 | 15 | 16 |
| 2017 | 15 | 20 |
| 2018 | 11 | 22 |
| 2019 | 12 | 26 |
| 2020 | 12 | 28 |
| 2021 | 14 | 39 |
| 2022 | 14 | 37 |
| 2023 | 8 | 25 |
| 2024 | 14 | 19 |
| 2025 | 22 | 21 |
| 2026 | 9 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Trojan circulating tumor cells8 Sep 2026US 12,728,140 B2Astrin Biosciences, Inc.
- Isolation of different extracellular vesicle (EV) subpopulations11 Aug 2026US 12,702,979 B2The Board of Trustees of the Leland Stanford Junior University
- Anti-CD47 monoclonal antibody and use thereof11 Aug 2026US 12,703,743 B2Akeso Biopharma, Inc.
- Membrane protein scaffolds for exosome engineering9 Jun 2026US 12,648,907 B2Lonza Sales AG
- Treatment of NSCLC patients refractory for anti-PD-1 antibody28 Apr 2026US 12,611,427 B2Iovance Biotherapeutics, Inc.
- Combination therapies using immuno-dash inhibitors and pge2 antagonists17 Sep 2026US 2026/0272880 A1Trustees of Tufts College
- Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof20 Aug 2026US 2026/0240999 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Reacted matrix for cell dispersion6 Aug 2026US 2026/0224614 A1The Texas A&M University System
- Silicified cell replicas, methods of making, and methods of using23 Jul 2026US 2026/0207723 A1UNM Rainforest Innovations
- Single-Cell Microsphere Prepared Based on Oil-Free Aqueous Two-Phase System Strategy and Preparation Method Therefor18 Jun 2026US 2026/0165971 A1Guangzhou Medical University
Most cited
By later US patents
- Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling161US 6,051,227 AThe Regents of the University of California Office of Technology Transfer · 2000
- Method and system for encapsulating cells in a tubular extrudate in separate cell compartments148US 5,158,881 ABrown University Research Foundation · 1992
- Redirection of cellular immunity by receptor chimeras135US 7,049,136 B2The General Hospital Corporation · 2006
- Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells108US 5,851,828 AThe General Hospital Corporation · 1998
- Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells99US 6,284,240 B1The General Hospital Corporation · 2001